UNSPSC 51142501: Bromocriptine

This classification denotes a neuroprotective agent with the molecular formula C32H40BrN5O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3A64E3G5ZO, chemically known as ergotaman-3,6,18-trione, 2-bromo-12-hydroxy-2-(1-methylethyl)-5-(2-methylpropyl)-, (5.alpha.)- but generally known as bromocriptine, which bears US NIH Compound Identifier 2443. Bromocriptine most often comes in base and mesilate (mesylate) forms.

UNSPSC 51142501 Bromocriptine is a Commodity code that nominally covers a specific pharmaceutical product, but recent state and local procurement activity under this code shows little alignment with the drug itself. The three opportunities posted in the past three months span athletic training services for municipal public safety agencies, medical aid supplies for fire rescue operations, and pharmaceutical procurement strategy research—none of which involve bromocriptine as an administered or stocked product. The issuing bodies include municipal departments (City of Tucson Fire and Police, City of Tampa Fire Rescue) and a state health agency (Texas Health and Human Services Commission), reflecting fragmented demand across local emergency services and state health administration rather than concentrated or recurring pharmaceutical supply activity.

The geographic activity covers Arizona, Florida, and Texas. The Tucson Fire and Police athletic training RFP (due June 9, 2026) seeks injury prevention and rehabilitation services with NATA BOC and NSCA TSAC-F certification requirements; the Tampa Fire Rescue ITB for medical aid supplies (posted April 24, 2026, due April 9, 2025) targets a 32-item list including bandages, pain relievers, and antiseptic products with a $100,000 budget and local small business set-asides; and the Texas HHS Commission RFI (posted April 3, 2026) solicits vendor capabilities for a direct-to-manufacturer prescription program without specifying bromocriptine or any particular drug. The code exhibits minimal relevant recent activity and appears to be a poor descriptor for the actual procurement being done under its number. Firms holding state pharmaceutical contracts or suppliers of bromocriptine to state health plans may wish to monitor this category for future pharmacy-specific solicitations, but current postings do not reflect active demand for this commodity.